Hydroxyethyl Starch

DB09106ApprovedInvestigationalSmall moleculePlasma Substitutes

Hydroxyethyl Starch is a plasma volume substitute used to treat and prevent hypovolemia. Hydroxyethyl starch (HES/HAES) is a nonionic starch derivative.

Mechanism
Curator reviewed
Primary indication
An intravenous solution of hydroxyethyl starch is used to prevent shock following severe blood loss caused by trauma, surgery, or other issues.Curator reviewed · 3 structured indications
First approval
Canada, 2002 · United States, 1991
Also known as
HAES · Hetastarch · Hydroxyethylstarch
Brand names
  • Hespan
  • Hextend
  • Volulyte
  • Voluven

Resolves to

Compound
UNII875Y4127EACAS9005-27-0ChEMBLCHEMBL2108448KEGGD03335
Clinical / RWD
RxNorm5531ATCB05AA07
Targets
P14780MMP9

What you can answer from here — as of July 03, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
730Drug interactionsStructured to mechanism, not free text
Sign in
112Clinical trialsPhase, status and sponsor resolved per trial
Sign in
3Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
12ContraindicationsEach with its own population and attribute set
Sign in
139Marketed productsAcross 10 countries and 21 labellers
Sign in
1ATC codeIncluding every combination product, plus 17 drug categories
Sign in
3+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Hydroxyethyl Starch, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In